Investor Relations
Reporting 2nd Quarter 2022
Evonik has published its quarterly report Q2 2022 on August 10, 2022.
You can access further information here. ... MORE
Investor Relations
Evonik is substituting up to 40 percent natural gas at its German sites
Evonik is making energy supply at its German sites significantly less dependent on natural gas. ... MORE
Investor Relations
Capital Markets Day 2022
On May 11, 2022 Evonik hosted its Capital Market Day for investors & financial analysts.
... MORE
Further Information
Company
Events & Presentations
Here you will find dates, information and presentations on our events. ... MORE
Company
Analysts' estimates
Evonik Industries AG is covered by German and international financial analysts, who provide their own research analyses and earnings estimates in respect of the company. ... MORE
Company
News & Reports
Here you can find "Investor Relations News" with the latest news from our company, plus our most recent interim reports, annual reports and corporate responsibility reports. ... MORE
Reporting 2022/2023
-
November 8, 2022Quarterly Report Q3 2022
-
March 2, 2023Quarterly Report Q4 2022
Investor Relations
Aug 10, 2022
Evonik grows strongly in the first half of the year and confirms outlook for adjusted EBITDA for 2022
Evonik closes the second quarter with strong results. ... MORE
Investor Relations
Aug 08, 2022
Evonik is substituting up to 40 percent natural gas at its German sites
Evonik is making energy supply at its German sites significantly less dependent on natural gas. ... MORE
Investor Relations
Aug 01, 2022
Evonik divests U.S. betaine business
Evonik, one of the world’s leading providers of personal care ingredients, is continuing its portfolio transformation to System Solutions by divesting its U.S. betaine business. ... MORE
Contact | Investor Relations
Jun 02, 2022
Evonik invests US$220 million in partnership with the U.S. Government to build new lipid production facility for mRNA-based therapies in the U.S.
Evonik, one of the world's leading providers of drug delivery technologies, is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the United States. ... MORE
Investor Relations
May 20, 2022
Evonik successfully issues second green bond
Evonik Industries AG successfully issued a green bond with a nominal volume of €750 million on Wednesday to refinance an upcoming bond maturity in January 2023 in the same volume. ... MORE
Investor Relations
May 16, 2022
Award for sustainability: Evonik receives platinum rating again
The EcoVadis rating agency has again awarded Evonik a platinum rating for its sustainability performance. ... MORE
Further Information
Company
Financial data
Evonik is active in over 100 countries around the world. In fiscal 2018 more than 36,000 employees generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion. ... MORE
Company
Bonds & Rating
Evonik maintains a centralized approach to financing. Liabilities for credit and loans are fully guaranteed by Evonik Industries AG. ... MORE
Company
Key Figures Share
Here you find information about Evonik shares. ... MORE
Company
Contact & Service
You can find the contacts in the Investor Relations Department here. ... MORE
Company
Disclaimer
Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained. ... MORE
Company
Corporate Governance
As a globally active company, we have to comply with a wide range of statutory regulations and cultural standards. ... MORE
Investor Relations
Sustainable Investment (SRI)
We accept responsibility for our businesses, our employees, the environment and the society. ... MORE